Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT03430037
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Frail Elderly Syndrome

Eligibility Criteria

Sex
FEMALE
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fisetin — DIETARY_SUPPLEMENT
    Flavonoid Family
  • Placebo oral capsule — DRUG
    Placebo

Study Details

This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.

Key Dates

Start date
Feb 6, 2018
Status verified
May 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
  • Placebo Comparator: Placebo
    Placebo capsules orally for 2 consecutive days, for 2 consecutive months.

Primary Outcome Measure

Improved 6 minute walk [ Time Frame: One Month ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies